Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2013; 34(01): 24-27
DOI: 10.4103/0971-5851.113411
CASE REPORT

Resistant metastatic penile carcinoma and response to biochemotherapy with paclitaxel and epidermal growth factor receptor monoclonal antibody, nimotuzumab

Avinash Pandey
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Vanita Noronha
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Amit Joshi
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Hemant Tongaonkar
Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Ganesh Bakshi
Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Kumar Prabhash
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

Carcinoma penis is one of the common malignancies in developing world especially among rural population. Multimodality treatment with surgery, radiation and chemotherapy for advanced penile carcinoma with groin nodal metastasis is crucial to optimise the outcome. Cisplatin, fluorouracil, methotrexate, vinorelbine, bleomycin and paclitaxel are the common chemotherapeutic agents used along with local therapy. Paucity of data to show superiority of one chemotherapeutic regime over another and only modest response to any combination chemotherapy. Progression of disease after surgery, radiation and chemotherapy is associated with poor outcome and quality of life. Nimotuzumab, Anti EGFR monoclonal antibody, along with paclitaxel in our case of resistant metastatic penile carcinoma has shown good symptomatic palliation and clinical response.

Keywords

Biochemotherapy - metastatic penile carcinoma - nimotuzumab


Publication History

Article published online:
20 July 2021

© 2013. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Misra S, Chaturvedi A, Misra NC. Penile carcinoma: A challenge for the developing world. Lancet Oncol 2004;5:240-7.
  • 2 Pow-Sang MR, Ferreira U, Pow-Sang JM, Nardi AC, Destefano V. Epidemiology and natural history of penile cancer. Urology 2010;76:S2-6.
  • 3 Kulkarni JN, Kamat MR. Prophylactic bilateral groin node dissection versus prophylactic radiotherapy and surveillance in patients with N0 and N1-2A carcinoma of the penis. Eur Urol 1994;26:123-8.
  • 4 Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
  • 5 Owor R. Carcinoma of the penis in Uganda. IARC Sci Publ 1984;63:493-7.
  • 6 HPV prevalence in penile carcinomas. Available from: http://www.apps.who.int/hpvcentre/statistics/dynamic/ico/country_pdf/IND.pdf. [Last accessed on 2013 Apr 08]
  • 7 Onuigbo WI. Carcinoma of skin of penis. Br J Urol 1985;57:465-6.
  • 8 Boon ME, Susanti I, Tasche MJ, Kok LP. Human papillomavirus (HPV)-associated male and female genital carcinomas in a Hindu population. The male as vector and victim. Cancer 1989;64:559-65.
  • 9 Gajalakshmi CK, Shanta V. Association between cervical and penile cancers in Madras, India. Acta Oncol 1993;32:617-20.
  • 10 Ahmed T, Sklaroff R, Yagoda A. Sequential trials of methotrexate, cisplatin and bleomycin for penile cancer. J Urol 1984;132:465-8.
  • 11 Sklaroff RB, Yagoda A. Cis-diamminedichloride platinum II (DDP) in the treatment of penile carcinoma. Cancer 1979;44:1563-5.
  • 12 Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: A Southwest Oncology Group study. J Urol 1999;161:1823-5.
  • 13 Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 1988;27:823-4.
  • 14 Modig H, Duchek M, Sjödin JG. Carcinoma of the penis. Treatment by surgery or combined bleomycin and radiation therapy. Acta Oncol 1993;32:653-5.
  • 15 Roth AD, Berney CR, Rohner S, Allal AS, Morel P, Marti MC, et al. Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: An active treatment modality with curative potential. Br J Cancer 2000;83:1637-42.
  • 16 Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636-45.
  • 17 Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: Preliminary results. Eur Urol 2009;55:546-51.
  • 18 Rubin GJ, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32.
  • 19 Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, Gascón P, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-77.
  • 20 Lavens N, Gupta R, Wood LA. EGFR overexpression in squamous cell carcinoma of the penis. Curr Oncol 2010;17:4-6.
  • 21 Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009;1:41-8.